围术期应用左西孟旦对急诊冠脉介入治疗的急性心肌梗死患者预后的影响

Effect of Applying Levosimendan in Perioperative Period on Prognosis of Patients with Acute Myocardial Infarction Treated by Emergency Coronary Intervention

摘要: 目的：探讨围术期应用左西孟旦治疗急性心肌梗死PCI术后患者高敏肌钙蛋白I、NT-proBNP、CRP指标的变化及临床意义。方法：选取2019年1月~2021年12月就诊于青岛市市立医院的92例患者作为研究对象，将所有患者随机分为两组：其中观察组46例(急诊PCI治疗 + 左西孟旦)，对照组46例(单纯急诊PCI治疗)，监测两组患者治疗前后高敏肌钙蛋白I、NT-proBNP、CRP指标的变化，并分析其临床意义。结果：治疗72 h及7天后，观察组患者在减轻高敏肌钙蛋白I、NT-proBNP、CRP等指标的持续上升优于对照组(P < 0.05)。结论：围术期应用左西孟旦可以有效减轻高敏肌钙蛋白I、NT-proBNP、CRP升高趋势。

Abstract: Objective: To investigate the changes and clinical significance of hypersensitive troponin I, NT-proBNP and CRP in patients with acute myocardial infarction treated with levosimendan during perioperative period after PCI. Methods: 92 patients in Qingdao Municipal Hospital from January 2019 to December 2021 were selected as the research object. All patients were randomly divided into two groups: 46 cases in the observation group (emergency PCI + levosimendan) and 46 cases in the control group (emergency PCI only). The changes of high-sensitivity troponin I, NT-proBNP and CRP indexes before and after treatment were monitored, and its clinical significance was analyzed. Results: 72 hours and 7 days after treatment, the patients in the observation group reduced the continuous rise of high-sensitivity troponin I, NT-proBNP and CRP better than the control group (P < 0.05). Conclusion: The perioperative application of levosimendan can effectively reduce the rising trend of high-sensitivity troponin I, NT-proBNP and CRP.